miR-142-5p regulates CD4+ T cells in human non-small cell lung cancer through PD-L1 expression via the PTEN pathway

被引:50
|
作者
Wan, Jun [1 ]
Ling, Xiean [1 ]
Peng, Bin [1 ]
Ding, Guanggui [1 ]
机构
[1] Jinan Univ, Clin Med Coll 2, Shenzhen Peoples Hosp, Dept Thorac Surg, 1017 DongMen North Rd, Shenzhen 518020, Guangdong, Peoples R China
基金
中国国家自然科学基金;
关键词
miR-142-5p; CD4(+) T cells; NSCLC; PD-L1; PTEN; ANTITUMOR; GENE; DIFFERENTIATION; POLYMORPHISMS; CARCINOMA; MODEL;
D O I
10.3892/or.2018.6439
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The present study aimed to evaluate the function of microRNA (miR)-142-5p on cancer immunity to induce apoptosis in human non-small cell lung cancer (NSCLC) and its mechanism. miR-142-5p expression was upregulated, and CD4(+) T cell levels were reduced in patients with NSCLC. Overexpression of miR-142-5p expression inhibited the cancer effects of CD4(+) T cells on NSCLC cell lines, and downregulation of miR-142-5p increased the cancer effects of CD4(+) T cells on NSCLC cell lines, compared with the control group. In addition, we found that overexpression of miR-142-5p suppressed PTEN protein expression and induced PI3K, p-Akt and PD-L1 protein expression in an in vitro model of NSCLC. Downregulation of miR-142-5p induced PTEN and PD-L1 protein expression and suppressed PI3K and p-Akt and protein expression in an in vitro model of NSCLC. The suppression of PD-L1 reduced the cancer effects of CD4(+) T cells on NSCLC cell lines following miR-142-5p downregulation. The inhibition of PTEN also reduced the cancer effects of CD4(+) T cells on NSCLC cell lines following miR-142-5p downregulation. Therefore, our study demonstrated that miR-142-5p regulated CD4(+) T cells in human NSCLC through PD-L1 expression via the PTEN pathway.
引用
收藏
页码:272 / 282
页数:11
相关论文
共 50 条
  • [31] PD-L1 expression in cell-blocks of non-small cell lung cancer: The impact of prolonged fixation
    Vigliar, Elena
    Iaccarino, Antonino
    Campione, Severo
    Campanino, Maria R.
    Clery, Eduardo
    Pisapia, Pasquale
    De Luca, Caterina
    Bellevicine, Claudio
    Malapelle, Umberto
    De Dominicis, Gianfranco
    Troncone, Giancarlo
    DIAGNOSTIC CYTOPATHOLOGY, 2020, 48 (07) : 595 - 603
  • [32] Butein suppresses PD-L1 expression via downregulating STAT1 in non-small cell lung cancer
    Zhao, Lin
    Zhang, Wenxin
    Luan, Fengming
    Chen, Xi
    Wu, Honghai
    He, Qiaojun
    Weng, Qinjie
    Ding, Ling
    Yang, Bo
    BIOMEDICINE & PHARMACOTHERAPY, 2023, 157
  • [33] Correlation Between PD-L1 Expression and Expression of CDK4 and SPOP in Non-Small Cell Lung Cancer
    Inoue, M.
    Yoshida, J.
    Oka, S.
    Honda, Y.
    Yasuda, D.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S924 - S924
  • [34] Tumor-Intrinsic PD-L1 Exerts an Oncogenic Function through the Activation of the Wnt/β-Catenin Pathway in Human Non-Small Cell Lung Cancer
    Ma, Yunxia
    Marinkova, Rumyana
    Nenkov, Miljana
    Jin, Lai
    Huber, Otmar
    Sonnemann, Juergen
    Peca, Natalia
    Gassler, Nikolaus
    Chen, Yuan
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (19)
  • [35] PD-L1 heterogeneity in patients with non-small cell lung cancer
    Wei, Zhigang
    Fan, Linlin
    Yang, Xia
    Li, Jie
    Zhan, Xuemei
    Ye, Xin
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 (05) : E268 - E274
  • [36] PD-L1 expression heterogeneity in non-small cell lung cancer: evaluation of small biopsies reliability
    Munari, Enrico
    Zamboni, Giuseppe
    Marconi, Marcella
    Sommaggio, Marco
    Brunelli, Matteo
    Martignoni, Guido
    Netto, George J.
    Moretta, Francesca
    Mingari, Maria Cristina
    Salgarello, Matteo
    Terzi, Alberto
    Picece, Vincenzo
    Pomari, Carlo
    Lunardi, Gianluigi
    Cavazza, Alberto
    Rossi, Giulio
    Moretta, Lorenzo
    Bogina, Giuseppe
    ONCOTARGET, 2017, 8 (52): : 90123 - 90131
  • [37] Comparison of PD-L1 mRNA Expression Measured with the CheckPoint Typer® Assay with PD-L1 Protein Expression Assessed with Immunohistochemistry in Non-small Cell Lung Cancer
    Erber, Ramona
    Stoehr, Robert
    Herlein, Stefanie
    Giedl, Claudia
    Rieker, Ralf Joachim
    Fuchs, Florian
    Ficker, Joachim H.
    Hartmann, Arndt
    Veltrup, Elke
    Wirtz, Ralph M.
    Brueckl, Wolfgang M.
    ANTICANCER RESEARCH, 2017, 37 (12) : 6771 - 6778
  • [38] PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?
    Grigg, Claud
    Rizvi, Naiyer A.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2016, 4
  • [39] The role of PD-L1 in EGFR-mutant non-small cell lung cancer
    Gao, Wentao
    Wang, Lingling
    Zhao, Yanyan
    Zhu, Lucheng
    DISCOVER ONCOLOGY, 2025, 16 (01)
  • [40] CircFOXK2 enhances tumorigenesis and immune evasion in non-small cell lung cancer by miR-485-5p/PD-L1 axis
    Zhang, Nan
    Fan, Jian
    Deng, Zhiping
    ANTI-CANCER DRUGS, 2022, 33 (05) : 437 - 447